Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Protara Therapeutics Shares Retrospective Analysis Of OK-432 In Rare Lymphatic Malformations

  • Protara Therapeutics Inc (NASDAQ:TARAannounced the results of a retrospective analysis of OK-432, the originator compound for TARA-002, its investigational therapy in development for lymphatic malformations (LMs), rare, congenital malformations of lymphatic vessels. 
  • The results from the analysis showed that OK-432 was clinically successful and generally well-tolerated in the treatment of both macrocystic and mixed-cystic LMs.
  • The retrospective analysis included 246 patients from a Phase 2 randomized study and 275 patients from an open-label study. 
  • In October, the FDA signed off Protara's Phase 1 trial of TARA-002 in adults with high-grade non-muscle invasive bladder cancer.
  • Approximately 69% of patients achieved clinical success in the immediate treatment group after six months, while only 7.5% of patients in the delayed treatment group showed spontaneous resolution.
  • 73.1% of patients in the open-label study achieved clinical success.
  • Patients were followed for up to three years post-treatment with no significant safety concerns.
  • Price Action: TARA shares are up 1.43% at $2.84 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.